| N | % |
---|---|---|
Age at Primary Dx | ||
  < 40 | 54 | 20.2 |
 40–49 | 101 | 37.8 |
 50–59 | 69 | 25.8 |
  ≥ 60 | 43 | 16.1 |
Stage at Primary Dx | ||
 1 | 62 | 23.2 |
 2 | 131 | 49.1 |
 3 | 59 | 22.1 |
 Unknown | 16 | 5.6 |
Grade at Primary Diagnosis | ||
 1 | 26 | 9.7 |
 2 | 135 | 50.6 |
 3 | 81 | 30.3 |
 9 (unknown) | 25 | 9.4 |
 ER + | 262 | 98.1 |
 PR+ | 218 | 81.7 |
 Chemotherapy Use | 214 | 80.1 |
Body Mass Index | ||
  < 25 | 61 | 22.8 |
 25–29.9 | 54 | 32.5 |
  > =30 | 51 | 30.7 |
 Missing | 101 | 37.8 |
PIK3CA mutated | 97 | 36.3 |
Medication use between primary and metastatic dx | ||
 Aspirin | 54 | 20.2 |
 NSAIDs | 85 | 31.8 |
 Aspirin or NSAIDs | 108 | 40.4 |
 Statins | 34 | 12.7 |
 Betablockers | 26 | 9.7 |
Typical Aspirin Dose among users | ||
 325mg | 15 | 27.8 |
 81mg | 28 | 51.8 |
 Missing | 11 | 20.4 |
Time to Metastasis | ||
  < 5 years | 129 | 48.3 |
 5–10 years | 66 | 24.7 |
  ≥ 10 years | 72 | 27.0 |